Teligent

84 articles with Teligent

• PAI further bolsters its portfolio with the acquisition of Teligent Sterile Injectable and Topical products

  2/3/2022

  Pharmaceutical Associates, Inc. (PAI) announces that it has acquired all of the generic and branded US marketing authorizations from Teligent Inc. (Teligent) for an undisclosed amount.

• Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

  10/14/2021

  Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S.

• Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

  8/16/2021

  Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the second quarter of 2021 and provided a business update.

• Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

  8/11/2021

  Teligent, Inc. today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update.

• Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders

  6/18/2021

  Teligent, Inc. announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented.

• Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

  5/25/2021

  Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the first quarter of 2021 and provided a business update.

• Teligent, Inc. to Hold Conference Call for First Quarter 2021 Financial Results on Tuesday May 25, 2020

  5/21/2021

  Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31, 2021 financial results and business update. Conference Call Information Date: Tuesday, May 25, 2021 Time: 8:30 a.m. Eastern Time

• Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update

  5/3/2021

  Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2020.

• Teligent Announces Hiring of Chief Financial Officer

  4/15/2021

  Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021.

• Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

  2/23/2021

  Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors

• Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

  2/16/2021

  Generic Pharmaceutical and Contract Manufacturing Industry Leader Joins Teligent Board, Effective Immediately

• Teligent Takes Strategic Steps to Recapitalize and Position Business for Success

  1/28/2021

  Completes $77 million debt-for-equity exchange with Series C noteholders and senior secured lenders at premiums of 60% and 30% to the 5 day VWAP

• Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

  1/22/2021

  Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission.

• Teligent, Inc. Announces Third Quarter 2020 Results

  12/31/2020

  Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.

• Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders - Nov 25, 2020

  11/25/2020

  Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November 25, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

• Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders - Nov 11, 2020

  11/11/2020

  Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020 and adjourned to November 11, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

• Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

  10/22/2020

  Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approve

• Teligent Announces Completion of Series D Convertible Note Exchange

  9/23/2020

  Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senior Notes due 2023 (the “New 2023 Notes”) in exchange for approximately $57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 4.75% Convertible Seni

• Teligent, Inc. Announces Second Quarter 2020 Results

  8/19/2020

  Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020. Financial Highlights Second Quarter 2020 vs. First Quarter 2020 Revenues of $13.6 million, an increase of $6.1 million or 82%, stronger demand for both US topical products and injectable products sold in Canada   Gross profit of $2.5 million, an increase of $3.7 mill

• Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020

  8/14/2020

  Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19 th , 2020 to discuss the 2 nd quarter 2020 financial results and business update. The Company invites you to listen to the call by dialing (866) 393-8366.  International participants should call (409) 350-3154.  Participants should ask to join the Teligent, Inc. call. This ca